This study demonstrated that alogliptin treatment significantly reduced postprandial levels of intestinally derived apo-B48–containing lipoproteins, which were induced by a conventional oral cookie loading test (28.5 g fat per person), and that alogliptin improved postprandial lipemia-induced endothelial dysfunction. Here, APOB is linked to hyperlipidemia.